A bis-quinoline ruthenium(ii) arene complex with submicromolar cytotoxicity in castration-resistant prostate cancer cells

A new Ru(II) arene chlorido organometallic complex [(eta(6)-p-cymene)(L)RuCl]PF6 (named as pCYRuL) using 2-bis(quinolin-2-ylmethylene) hydrazine (L) was developed that exhibits potent anticancer activity against castration-resistant prostate cancer (CRPC) (IC50 = 0.71 mu M), and it is 45 times more effective than the standard drug cisplatin (IC50 = 31.3 mu M) in a castration-resistant human prostatic adenocarcinoma cell line (PC-3) but non-toxic in normal human kidney cells (HK2) as well as normal breast cells (MCF10A) and found that pCYRuL exerted anticancer activity via apoptosis induction and cell cycle arrest in the G2/M phase of PC-3 cells.